# Gilead Sciences HIV treatment developments

> Live situation record from CLSTR: https://clstr.news/situations/gilead-sciences-hiv-treatment-developments
> Updated: 2026-08-31T18:31:58.000Z. Sources: 4. Developments: 2.

The U.S. Food and Drug Administration (FDA) has approved Gilead Sciences’ Bixlenvo, a once-daily single-pill HIV treatment. The medication combines bictegravir and lenacapavir to assist adult patients who have suppressed viral loads but require a less complex regimen than their current multi-drug therapies. Clinical trials indicated the combination maintained viral suppression over 48 weeks.

In related developments regarding lenacapavir, an international Phase 3 trial (ISLEND-2) involving 626 adults across 14 countries found that an experimental once-weekly pill combining Merck’s islatravir and Gilead’s lenacapavir was as effective as standard daily therapy, maintaining viral suppression in nearly all participants after 48 weeks.

## Timeline

### 2026-08-31: Gilead Sciences receives FDA approval for new once-daily HIV pill

New advancements in HIV treatment include the FDA approval of Gilead’s once-daily Bixlenvo pill and successful Phase 3 trial results for a potential once-weekly oral treatment.

2 sources. https://clstr.news/cluster/gilead-sciences-receives-fda-approval-for-new-once-daily-hiv-pill

### 2026-08-27: Gilead Sciences receives FDA approval for Bixlenvo HIV treatment

The FDA has approved Gilead Sciences’ Bixlenvo, a once-daily HIV pill combining bictegravir and lenacapavir to provide a simplified treatment option for patients with drug resistance or complex medication needs

2 sources. https://clstr.news/cluster/gilead-sciences-receives-fda-approval-for-bixlenvo-hiv-treatment

---
Cite as: Gilead Sciences HIV treatment developments. CLSTR, https://clstr.news/situations/gilead-sciences-hiv-treatment-developments